JAGSONPAL PHARMACEUTICALS
|
JAGSONPAL PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.34 | 8.50 | 10.20 | 7.20 | 6.51 |
| CEPS(Rs) | 9.56 | 3.65 | 4.26 | 3.11 | 2.77 |
| DPS(Rs) | 2.50 | 5.00 | 5.00 | 4.00 | 1.00 |
| Book NAV/Share(Rs) | 32.83 | 64.43 | 57.30 | 50.68 | 43.55 |
| Tax Rate(%) | 20.75 | 24.79 | 23.24 | 29.23 | 22.01 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.12 | 10.28 | 13.28 | 10.32 | 10.15 |
| EBIT Margin(%) | 25.13 | 13.68 | 13.70 | 11.11 | 11.91 |
| Pre Tax Margin(%) | 24.79 | 13.31 | 13.54 | 10.99 | 11.64 |
| PAT Margin (%) | 19.65 | 10.01 | 10.39 | 7.78 | 9.08 |
| Cash Profit Margin (%) | 22.53 | 10.75 | 10.86 | 8.41 | 9.65 |
| Performance Ratios | |||||
| ROA(%) | 21.44 | 10.52 | 14.29 | 11.24 | 10.90 |
| ROE(%) | 28.51 | 14.02 | 18.89 | 15.28 | 15.70 |
| ROCE(%) | 33.14 | 17.72 | 24.15 | 21.23 | 19.43 |
| Asset Turnover(x) | 1.09 | 1.05 | 1.38 | 1.44 | 1.20 |
| Sales/Fixed Asset(x) | 4.91 | 10.09 | 5.65 | 4.10 | 3.18 |
| Working Capital/Sales(x) | 2.08 | 1.40 | 1.88 | 2.95 | 2.35 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.20 | 0.10 | 0.18 | 0.24 | 0.31 |
| Receivable days | 15.63 | 25.88 | 25.87 | 21.26 | 33.13 |
| Inventory Days | 19.56 | 29.02 | 35.78 | 44.76 | 57.34 |
| Payable days | 32.80 | 55.17 | 69.43 | 75.08 | 67.24 |
| Valuation Parameters | |||||
| PER(x) | 25.90 | 13.17 | 28.42 | 43.57 | 12.22 |
| PCE(x) | 22.58 | 30.67 | 27.20 | 40.31 | 11.49 |
| Price/Book(x) | 6.58 | 4.34 | 5.06 | 6.19 | 1.83 |
| Yield(%) | 1.16 | 1.79 | 1.72 | 1.28 | 1.26 |
| EV/Net Sales(x) | 4.86 | 2.84 | 2.72 | 3.66 | 0.82 |
| EV/Core EBITDA(x) | 22.02 | 18.30 | 16.17 | 27.99 | 6.60 |
| EV/EBIT(x) | 18.43 | 19.29 | 18.31 | 29.57 | 6.92 |
| EV/CE(x) | 5.44 | 3.16 | 4.06 | 6.00 | 1.28 |
| M Cap / Sales | 5.34 | 3.55 | 3.21 | 3.78 | 1.11 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 28.76 | -11.83 | 8.79 | 15.77 | 18.53 |
| Core EBITDA Growth(%) | 83.21 | -18.90 | 40.18 | 21.22 | 112.25 |
| EBIT Growth(%) | 130.80 | -12.89 | 30.81 | 20.29 | 125.46 |
| PAT Growth(%) | 146.45 | -15.94 | 41.72 | 10.53 | 116.73 |
| EPS Growth(%) | -1.87 | -16.70 | 41.72 | 10.53 | 116.73 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | 0.06 |
| Current Ratio(x) | 6.22 | 9.39 | 4.89 | 3.40 | 2.98 |
| Quick Ratio(x) | 5.64 | 8.61 | 4.31 | 2.53 | 2.25 |
| Interest Cover(x) | 73.92 | 37.69 | 85.28 | 94.48 | 43.59 |
| Total Debt/Mcap(x) | - | - | - | - | 0.03 |
Compare Financial Ratios of peers of JAGSONPAL PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JAGSONPAL PHARMACEUTICALS | ₹1,475.6 Cr | -3.5% | 5.3% | -1.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹468,458.0 Cr | 0.7% | 8.1% | 16% | Stock Analytics | |
| DIVIS LABORATORIES | ₹193,383.0 Cr | 7% | 10.2% | 3.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹169,829.0 Cr | 2.5% | 11.3% | 49.6% | Stock Analytics | |
| CIPLA | ₹116,164.0 Cr | -0.3% | 4.1% | -3.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,648.0 Cr | -3.2% | -3.9% | -3% | Stock Analytics | |
JAGSONPAL PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JAGSONPAL PHARMACEUTICALS | -3.5% |
5.3% |
-1.4% |
| SENSEX | 0.9% |
2.2% |
-7.5% |
You may also like the below Video Courses
